Bavencio (Avelumab) is a monoclonal antibody that targets PD-L1 (programmed death-ligand 1), a protein involved in suppressing immune system activity. By inhibiting PD-L1, Bavencio restores immune system activity, enabling it to detect and attack cancer cells. It is used in the treatment of advanced cancers, particularly metastatic Merkel cell carcinoma and urothelial carcinoma.

Indications: 

1. Metastatic Merkel Cell Carcinoma (MCC):
   • As a single agent for adult and pediatric patients 12 years and older.
2. Advanced Urothelial Carcinoma:
   • For patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
3. Advanced Renal Cell Carcinoma (RCC):
   • In combination with axitinib for first-line treatment of advanced RCC.

Bavencio works by binding to the PD-L1 protein on cancer cells. This prevents PD-L1 from interacting with the PD-1 receptor on T-cells, a mechanism that suppresses immune response. By blocking this interaction, Bavencio enables T-cells to recognize and destroy cancer cells.